Karolinska Development’s portfolio company Dilafor has completed recruitment to an extension study of tafoxiparin

STOCKHOLM, SWEDEN – December 27, 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Dilafor has enrolled the last patient to an extension of the clinical phase 2b trial with its drug candidate tafoxiparin, which generated positive results in June 2021. The purpose of the extension study is to document the effect of tafoxiparin at further doses.

Up to 30 percent of all pregnant women are subject to planned start of labor, which increases the risk of medical complications in both mother and child and leads to high healthcare costs. The clinical phase 2b study of tafoxiparin that was completed in June 2021 showed a significant positive effect on cervix ripening in first-time mothers that were given treatment for a planned start of labor. The ongoing extension study includes 164 women, and the results are expected to be presented during the first quarter of 2023.

“Following the positive results from the phase 2b study of Dilafor’s drug candidate tafoxiparin last year, we are now looking forward to the results from the extension study. By continuously strengthening the clinical documentation of tafoxiparin, our portfolio company is increasing the opportunities to attract commercial partners to this important project, which has the potential to reduce the risk of complications for both mother and child in connection with childbirth,” says Viktor Drvota, CEO, Karolinska Development.

Karolinska Development's direct ownership in Dilafor amounts to 1% and indirect ownership interest via KDev Investment in Dilafor amounts to 30%.

For further information, please contact:

Viktor Drvota, CEO, Karolinska Development AB

Phone: 2, e-mail:

Johan Dighed, General Counsel and Deputy CEO, Karolinska Development AB

Phone: +46 70 207 48 26, e-mail:

TO THE EDITORS

About Karolinska Development AB



Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patient’s lives while providing an attractive return on investment to shareholders.

Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.

Karolinska Development has a portfolio of eleven companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.

The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.

For more information, please visit .

Attachment